General Proximity

General Proximity is an early-stage biotech leveraging a proprietary proximity discovery engine, OmniTAC™, to create novel therapeutics that modulate protein function by controlling intracellular proximity events. The company has secured backing from leading technical investors and major grants, and has established a multi-target collaboration with Daiichi Sankyo in oncology. With a seasoned team from top academic and industry institutions, General Proximity is positioned to advance a pipeline of proximity medicines, though it remains pre-clinical and pre-revenue.

OmniTAC™ - a generalized, mechanism-agnostic, unbiased proximity discovery platform that screens the 'effectome' to identify optimal effector proteins for inducing therapeutic proximity events with disease targets, enabling a range of outcomes beyond degradation.

General Proximity competes in the rapidly evolving field of induced proximity therapeutics, directly against companies focused on protein degradation (e.g., Arvinas, Kymera, Nurix) and other proximity modalities like molecular glues. It also competes broadly with all modalities targeting oncology and immunology. Its key differentiation is the claim of a generalized, mechanism-agnostic platform, as opposed to platforms focused on a single outcome like degradation.